Table of Contents Author Guidelines Submit a Manuscript
Advances in Medicine
Volume 2014, Article ID 947923, 5 pages
http://dx.doi.org/10.1155/2014/947923
Research Article

Ivacaftor Therapy in CF Patients: Single Center Experience

1Department of Pediatrics, University of Florida, 1600 SW Archer Road, Suite HD 604, P.O. Box 100296, Gainesville, FL 32610, USA
2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida, 1600 SW Archer Road, P.O. Box 100225, Gainesville, FL 32610, USA
3Division of Pediatric Pulmonary Medicine, Department of Pediatrics, University of Florida, 1600 SW Archer Road, P.O. Box 100296, Gainesville, FL 32610, USA

Received 8 May 2014; Revised 3 September 2014; Accepted 15 September 2014; Published 22 October 2014

Academic Editor: Gernot Zissel

Copyright © 2014 Pritish Mondal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. M. Farrell, B. J. Rosenstein, T. B. White et al., “ Guidelines for diagnosis of cystic fibrosis in newborns through older adults: cystic fibrosis foundation consensus report,” Journal of Pediatrics, vol. 153, no. 2, pp. S4–S14, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. “Cystic fibrosis mutation database,” http://www.genet.sickkids.on.ca/app.
  3. B. W. Ramsey, J. Davies, N. G. McElvaney et al., “A CFTR potentiator in patients with cystic fibrosis and the G551D mutation,” The New England Journal of Medicine, vol. 365, no. 18, pp. 1663–1672, 2011. View at Publisher · View at Google Scholar
  4. S. M. Rowe, S. L. Heltshe, T. Gonska et al., “Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis,” The American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 2, pp. 175–184, 2014. View at Publisher · View at Google Scholar
  5. J. Kaiser, “New cystic fibrosis drug offers hope, at a price,” Science, vol. 335, no. 6069, p. 645, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. Five withdrawn drugs, 2013, http://www.forbes.com/2004/12/10/cx_mh_1213withdrawnslide.html?thisSpeed=6000.
  7. Merck hit with $285,000 verdict in fosamax trial, 2013, http://www.reuters.com/article/2013/02/05/us-merck-fosamax-idUSBRE91416H20130205.
  8. A. Bush, M. E. Hodson, D. M. Geddes et al., “Dornase alfa for cystic fibrosis. Patients should not be denied a safe, effective treatment,” The British Medical Journal, vol. 310, no. 6993, p. 1533, 1995. View at Google Scholar · View at Scopus
  9. “Costly drug vertex is denied, and medicaid patients sue,” The Wall Street Journal, 2014, http://online.wsj.com/articles/costly-drug-vertex-is-denied-and-medicaid-patients-sue-1405564205?KEYWORDS=kalydeco.
  10. M. D. Bellin, T. Laguna, J. Leschyshyn et al., “Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study,” Pediatric Diabetes, vol. 14, no. 6, pp. 417–421, 2013. View at Publisher · View at Google Scholar · View at Scopus